Hutch News

New Science Spotlight Articles

Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
10 NEW August 26, 2019

Seattle team pivotal to FDA OK on drug for rare skin cancer

UW Medicine and Fred Hutch had key roles in clinical trial of immunotherapy option for often-lethal Merkel cell cancer
Releases - December 20, 2018

Molecular mechanisms of late cancer relapse

from the Chapuis lab, Clinical Research Division
Science Spotlight - October 15, 2018

Cancer cells evade immunotherapy by hiding telltale marker, suggesting how to stop relapse

A Nature Communications report explains why some Merkel cell carcinoma patients treated with immunotherapy see their cancers shrink at first but then come back.
Releases - September 24, 2018

Triple therapy for rare skin cancer shows promise in small, early-stage trial

Combo of T-cell therapy, newly FDA-approved drug and another immune booster kept cancer at bay for three of four patients with metastatic Merkel cell carcinoma
Hutch News - May 31, 2017

With immunotherapy trial, ‘a real paradigm shift’ in rare skin cancer

Investigators report ‘extraordinarily’ long-lasting treatment responses in patients with chemo-resistant, metastatic Merkel cell carcinoma
Hutch News - April 03, 2017

Immunotherapy drug becomes first therapy approved by FDA for rare skin cancer

Benefit seen in nearly one-third of patients ‘with no hope at all of surviving’ their treatment-resistant Merkel cell carcinoma
Hutch News - March 24, 2017

A new blood test detects recurrence of rare skin cancer

$200 assay can accurately signal return of Merkel cell carcinoma — in some cases catching tumors earlier than expensive imaging
Hutch News - December 12, 2016
Last Modified, August 15, 2019